Isbn: 9783659106972 - Docking Studies of Bcr-abl and C-abl by Structural Analogues of Gnf-2: in Silico Analysis of Myristate Binding Site (3 results)

ISBN
Refine with Advanced Search

Refine your search

  • Books (3)

to

Custom price range (£)

to

  • Language: English

    Published by LAP LAMBERT Academic Publishing, 2012

    3659106976 / 9783659106972

    • Softcover

    Seller: Mispah books, Redhill, SURRE, United KingdomMispah books

    4-star seller
    Contact seller

    Condition: Used - As new

    £ 101.00

    £ 25.00 shipping 
    Ships from United Kingdom to U.S.A.

    Quantity: 1 available

    Paperback. Condition: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Language: English

    Published by LAP LAMBERT Academic Publishing, 2012

    3659106976 / 9783659106972

    • Softcover
    • Print on Demand

    Seller: moluna, Greven, Germanymoluna

    5-star seller
    Contact seller

    Condition: New

    £ 36.88

    £ 42.09 shipping 
    Ships from Germany to U.S.A.

    Quantity: Over 20 available

    Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Bhatt DrushtiPursuing M.Phil Bioinformatics from Gujarat University, Ahmedabad, India. Completed research work on cancer biology especially Chronic myelocytic leukaemia(CML) and Acute myelocytic leukaemia(AML). Presently working on t.

  • Language: English

    Published by LAP Lambert Academic Publishing, 2012

    3659106976 / 9783659106972

    • Softcover
    • Print on Demand

    Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH

    5-star seller
    Contact seller

    Condition: New

    £ 62.83

    £ 26.21 shipping 
    Ships from Germany to U.S.A.

    Quantity: 2 available

    Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - In an attempt to search for new pharmacological approach to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, allosteric inhibitors had been discovered. The ATP-competitive inhibitors nilotinib and dasatinib, which bind to catalytically different conformation of the Abl kinase domain, had been approved for the targeting most of imatinib-resistant CML, fail to effectively suppress the Bcr-Abl activity of T351I (gatekeeper) mutation. The GNF-2, class of compound that inhibits Bcr-Abl kinase activity through an allosteric non-ATP competitive mechanism. The GNF-2 binds to myristate-binding site of Abl, leading to change in structure of ATP-binding-site. The GNF-5, an analogue of GNF-2 has appropriate pharmacokinetic properties, used in simultaneous binding of ATP-binding-inhibitors imatinib and nilotinib to obscure resistant mutation in Bcr-Abl. The aim of this work is to analyse the different structural analogues of GNF-2, which can be used as therapeutic agent to treat Chronic Myelogenous Leukemia (CML).